Alchemab Therapeutics Lands $34M in Largest UK Life Sciences Deal

Jan de Vries · 2026-07-09

Alchemab Therapeutics, a London-based clinical-stage BioTech startup, just scored a massive vote of confidence from the British Business Bank. The bank injected $34 million (about £25 million) into the company, marking its biggest life sciences investment ever. This new cash brings Alchemab's total Series A funding to a whopping $148 million (around £109 million). And they've got big plans for it. They'll use the money to expand their clinical pipeline, grow their antibody dataset from 500 million to a billion sequences, and push more drug candidates into clinical trials. ### Why This Deal Matters It's not every day you see a government-backed bank make this kind of bet on a startup. The British Business Bank is essentially saying, "We believe in this company's science." And that's huge for the UK's life sciences scene. Dr. Jane Osbourn, Alchemab's CEO and co-founder, put it this way: "We are delighted that British Business Bank has recognized the importance of enabling Alchemab to grow and thrive here in the UK. This investment provides further validation of the sustainable, long-term potential of our drug discovery platform." ### What Alchemab Actually Does Founded in 2019, Alchemab takes a unique approach to drug discovery. Instead of starting from scratch in a lab, they look at people who naturally resist disease. Think about it: some folks get exposed to nasty illnesses but never get sick. Why? Their immune systems have something special. Alchemab finds these resilient individuals and studies their antibodies. They sequence B cells from these people, generating millions of antibody sequences. Then their AI-powered platform, called Resiliome, sifts through all that data to identify the antibodies that provide protection. Here's the simple version: - Find people who are resistant to a disease - Sequence their immune cells to find protective antibodies - Use AI to identify the best candidates - Develop those into drugs for patients who aren't so lucky ### The Bigger Picture This investment builds on some serious momentum. Alchemab's lead drug, ATLX-1282, is already in clinical development for ALS (amyotrophic lateral sclerosis, also known as Lou Gehrig's disease). In May 2025, they signed a licensing deal with Eli Lilly worth up to $415 million. Under that agreement, Alchemab will run early Phase 1 trials, then Lilly takes over for further development and commercialization. Dr. Carmine Circelli, Senior Investment Director at British Business Bank, summed up the potential: "Alchemab is yet another example of the UK's strength in leveraging technology in life sciences. By combining one of the world's largest proprietary antibody datasets with advanced AI, the company has developed a powerful platform with the potential to unlock new treatments." ### What This Means for You If you're watching the European startup scene, this is a signal. The UK is still a powerhouse for biotech, and AI-driven drug discovery is attracting serious capital. For US investors and professionals, it's worth keeping an eye on companies like Alchemab that blend biology with machine learning. The playbook is simple: find natural biological solutions, scale them with tech, and partner with pharma giants for commercialization.